Do analysts prefer AYTU or AIFC?

Aytu BioPharma currently has a consensus target price of $10.75, indicating a potential upside of 400.00%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Aytu BioPharma is more favorable than ALT5 Sigma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aytu BioPharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, AYTU or AIFC?

Aytu BioPharma has higher revenue and earnings than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aytu BioPharma $56.60M 0.41 -$13.56M -$4.58 N/A ALT5 Sigma $24.70M 3.40 -$344.51M N/A N/A

Is AYTU or AIFC more profitable?

Aytu BioPharma has a net margin of -60.17% compared to ALT5 Sigma's net margin of -2,483.94%. ALT5 Sigma's return on equity of -68.25% beat Aytu BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Aytu BioPharma -60.17% -69.93% -13.25% ALT5 Sigma -2,483.94% -68.25% -62.43%

Aytu BioPharma (AYTU) Competitors

$2.15 -0.01 (-0.46%)

Closing price 07/2/2026 03:56 PM Eastern

Extended Trading

$2.16 +0.01 (+0.47%)

As of 07/2/2026 06:16 PM Eastern

Compare

AYTU vs. PMN, RANI, ATRA, ANIX, and AIFC

Should you buy Aytu BioPharma stock or one of its competitors? MarketBeat compares Aytu BioPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aytu BioPharma include Promis Neurosciences (PMN), Rani Therapeutics (RANI), Atara Biotherapeutics (ATRA), Anixa Biosciences (ANIX), and ALT5 Sigma (AIFC). These companies are all part of the "pharmaceutical products" industry.

How does Aytu BioPharma compare to Promis Neurosciences?

Promis Neurosciences (NASDAQ:PMN) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

Promis Neurosciences currently has a consensus price target of $26.50, indicating a potential upside of 98.50%. Aytu BioPharma has a consensus price target of $10.75, indicating a potential upside of 400.00%. Given Aytu BioPharma's higher probable upside, analysts plainly believe Aytu BioPharma is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Aytu BioPharma has higher revenue and earnings than Promis Neurosciences. Promis Neurosciences is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A
Aytu BioPharma	$56.60M	0.41	-$13.56M	-$4.58	N/A

Promis Neurosciences has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. Aytu BioPharma's return on equity of -69.93% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Promis Neurosciences	N/A	-237.99%	-151.04%
Aytu BioPharma	-60.17%	-69.93%	-13.25%

50.1% of Promis Neurosciences shares are held by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are held by institutional investors. 1.5% of Promis Neurosciences shares are held by company insiders. Comparatively, 4.9% of Aytu BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Promis Neurosciences has a beta of -0.23, meaning that its share price is 123% less volatile than the broader market. Comparatively, Aytu BioPharma has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

In the previous week, Promis Neurosciences had 1 more articles in the media than Aytu BioPharma. MarketBeat recorded 1 mentions for Promis Neurosciences and 0 mentions for Aytu BioPharma. Promis Neurosciences' average media sentiment score of 0.50 beat Aytu BioPharma's score of 0.00 indicating that Promis Neurosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Promis Neurosciences	Positive
Aytu BioPharma	Neutral

Summary

Aytu BioPharma beats Promis Neurosciences on 9 of the 16 factors compared between the two stocks.

How does Aytu BioPharma compare to Rani Therapeutics?

Rani Therapeutics (NASDAQ:RANI) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

Rani Therapeutics presently has a consensus price target of $8.75, indicating a potential upside of 1,034.45%. Aytu BioPharma has a consensus price target of $10.75, indicating a potential upside of 400.00%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Rani Therapeutics is more favorable than Aytu BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Aytu BioPharma has higher revenue and earnings than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.63M	58.62	-$29.67M	-$0.41	N/A
Aytu BioPharma	$56.60M	0.41	-$13.56M	-$4.58	N/A

Rani Therapeutics has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. Aytu BioPharma's return on equity of -69.93% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-206.46%	-83.95%
Aytu BioPharma	-60.17%	-69.93%	-13.25%

30.2% of Rani Therapeutics shares are held by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are held by institutional investors. 26.7% of Rani Therapeutics shares are held by company insiders. Comparatively, 4.9% of Aytu BioPharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Rani Therapeutics had 1 more articles in the media than Aytu BioPharma. MarketBeat recorded 1 mentions for Rani Therapeutics and 0 mentions for Aytu BioPharma. Rani Therapeutics' average media sentiment score of 0.00 equaled Aytu BioPharma'saverage media sentiment score.

Company	Overall Sentiment
Rani Therapeutics	Neutral
Aytu BioPharma	Neutral

Rani Therapeutics has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, Aytu BioPharma has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market.

Summary

Rani Therapeutics beats Aytu BioPharma on 9 of the 15 factors compared between the two stocks.

How does Aytu BioPharma compare to Atara Biotherapeutics?

Atara Biotherapeutics (NASDAQ:ATRA) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

Atara Biotherapeutics has a net margin of -40.91% compared to Aytu BioPharma's net margin of -60.17%. Aytu BioPharma's return on equity of -69.93% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%
Aytu BioPharma	-60.17%	-69.93%	-13.25%

70.9% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are owned by institutional investors. 41.2% of Atara Biotherapeutics shares are owned by company insiders. Comparatively, 4.9% of Aytu BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Atara Biotherapeutics has a beta of 0.08, meaning that its stock price is 92% less volatile than the broader market. Comparatively, Aytu BioPharma has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

Atara Biotherapeutics has higher revenue and earnings than Aytu BioPharma. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.87	$32.69M	-$0.67	N/A
Aytu BioPharma	$56.60M	0.41	-$13.56M	-$4.58	N/A

In the previous week, Atara Biotherapeutics' average media sentiment score of 0.00 equaled Aytu BioPharma'saverage media sentiment score.

Company	Overall Sentiment
Atara Biotherapeutics	Neutral
Aytu BioPharma	Neutral

Atara Biotherapeutics currently has a consensus price target of $9.50, indicating a potential downside of 18.45%. Aytu BioPharma has a consensus price target of $10.75, indicating a potential upside of 400.00%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe Aytu BioPharma is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Atara Biotherapeutics and Aytu BioPharma tied by winning 7 of the 14 factors compared between the two stocks.

How does Aytu BioPharma compare to Anixa Biosciences?

Anixa Biosciences (NASDAQ:ANIX) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Anixa Biosciences has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market. Comparatively, Aytu BioPharma has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

Anixa Biosciences has higher earnings, but lower revenue than Aytu BioPharma. Anixa Biosciences is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	529.74	-$10.93M	-$0.31	N/A
Aytu BioPharma	$56.60M	0.41	-$13.56M	-$4.58	N/A

Anixa Biosciences has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. Aytu BioPharma's return on equity of -69.93% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-71.12%	-62.88%
Aytu BioPharma	-60.17%	-69.93%	-13.25%

In the previous week, Anixa Biosciences had 3 more articles in the media than Aytu BioPharma. MarketBeat recorded 3 mentions for Anixa Biosciences and 0 mentions for Aytu BioPharma. Aytu BioPharma's average media sentiment score of 0.00 beat Anixa Biosciences' score of -0.32 indicating that Aytu BioPharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Anixa Biosciences	Neutral
Aytu BioPharma	Neutral

29.1% of Anixa Biosciences shares are owned by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are owned by institutional investors. 26.4% of Anixa Biosciences shares are owned by insiders. Comparatively, 4.9% of Aytu BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Anixa Biosciences currently has a consensus price target of $8.50, indicating a potential upside of 159.94%. Aytu BioPharma has a consensus price target of $10.75, indicating a potential upside of 400.00%. Given Aytu BioPharma's higher probable upside, analysts plainly believe Aytu BioPharma is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Anixa Biosciences beats Aytu BioPharma on 9 of the 16 factors compared between the two stocks.

How does Aytu BioPharma compare to ALT5 Sigma?

Aytu BioPharma (NASDAQ:AYTU) and ALT5 Sigma (NASDAQ:AIFC) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

Aytu BioPharma has higher revenue and earnings than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$56.60M	0.41	-$13.56M	-$4.58	N/A
ALT5 Sigma	$24.70M	3.40	-$344.51M	N/A	N/A

33.5% of Aytu BioPharma shares are held by institutional investors. Comparatively, 6.3% of ALT5 Sigma shares are held by institutional investors. 4.9% of Aytu BioPharma shares are held by company insiders. Comparatively, 0.2% of ALT5 Sigma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Aytu BioPharma has a net margin of -60.17% compared to ALT5 Sigma's net margin of -2,483.94%. ALT5 Sigma's return on equity of -68.25% beat Aytu BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-60.17%	-69.93%	-13.25%
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%

In the previous week, ALT5 Sigma had 1 more articles in the media than Aytu BioPharma. MarketBeat recorded 1 mentions for ALT5 Sigma and 0 mentions for Aytu BioPharma. Aytu BioPharma's average media sentiment score of 0.00 equaled ALT5 Sigma'saverage media sentiment score.

Company	Overall Sentiment
Aytu BioPharma	Neutral
ALT5 Sigma	Neutral

Aytu BioPharma currently has a consensus target price of $10.75, indicating a potential upside of 400.00%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Aytu BioPharma is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Aytu BioPharma has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, ALT5 Sigma has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market.

Summary

Aytu BioPharma beats ALT5 Sigma on 9 of the 13 factors compared between the two stocks.

Get Aytu BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AYTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AYTU vs. The Competition

Export

Metric	Aytu BioPharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$23.18M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-0.47	21.61	28.02	24.70
Price / Sales	0.41	340.19	540.37	99.49
Price / Cash	5.75	147.12	49.26	57.09
Price / Book	1.02	8.66	10.96	6.46
Net Income	-$13.56M	$23.81M	$3.57B	$337.01M
7 Day Performance	-0.92%	3.39%	2.12%	1.69%
1 Month Performance	-4.44%	10.81%	5.25%	3.81%
1 Year Performance	-11.34%	62.61%	33.29%	23.90%

Aytu BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AYTU Aytu BioPharma	2.3483 of 5 stars	$2.15 -0.5%	$10.75 +400.0%	-11.3%	$23.18M	$56.60M	N/A	160
PMN Promis Neurosciences	3.7127 of 5 stars	$10.69 +0.1%	$26.50 +147.9%	+15.3%	$95.78M	N/A	N/A	5	Analyst Forecast Gap Up
RANI Rani Therapeutics	1.8945 of 5 stars	$0.76 -2.3%	$8.75 +1,058.9%	+43.4%	$95.72M	$1.63M	N/A	110
ATRA Atara Biotherapeutics	0.6962 of 5 stars	$11.16 +5.2%	$9.50 -14.9%	+45.4%	$95.60M	$120.77M	N/A	330
ANIX Anixa Biosciences	4.1908 of 5 stars	$2.76 -0.4%	$8.50 +208.0%	-2.4%	$94.24M	$210K	N/A	5	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AYTU) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aytu BioPharma (AYTU) Competitors

AYTU vs. PMN, RANI, ATRA, ANIX, and AIFC

How does Aytu BioPharma compare to Promis Neurosciences?

Summary

How does Aytu BioPharma compare to Rani Therapeutics?

Summary

How does Aytu BioPharma compare to Atara Biotherapeutics?

Summary

How does Aytu BioPharma compare to Anixa Biosciences?

Summary

How does Aytu BioPharma compare to ALT5 Sigma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AYTU vs. The Competition

Aytu BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aytu BioPharma (AYTU) Competitors

AYTU vs. PMN, RANI, ATRA, ANIX, and AIFC

How does Aytu BioPharma compare to Promis Neurosciences?

Do analysts prefer PMN or AYTU?

Which has better valuation and earnings, PMN or AYTU?

Is PMN or AYTU more profitable?

Do institutionals & insiders have more ownership in PMN or AYTU?

Which has more risk & volatility, PMN or AYTU?

Does the media favor PMN or AYTU?

Summary

How does Aytu BioPharma compare to Rani Therapeutics?

Do analysts rate RANI or AYTU?

Which has higher valuation and earnings, RANI or AYTU?

Is RANI or AYTU more profitable?

Do insiders and institutionals have more ownership in RANI or AYTU?

Does the media favor RANI or AYTU?

Which has more risk & volatility, RANI or AYTU?

Summary

How does Aytu BioPharma compare to Atara Biotherapeutics?

Is ATRA or AYTU more profitable?

Do insiders and institutionals believe in ATRA or AYTU?

Which has more volatility & risk, ATRA or AYTU?

Which has preferable valuation and earnings, ATRA or AYTU?

Does the media refer more to ATRA or AYTU?

Do analysts rate ATRA or AYTU?

Summary

How does Aytu BioPharma compare to Anixa Biosciences?

Which has more risk & volatility, ANIX or AYTU?

Which has preferable earnings and valuation, ANIX or AYTU?

Is ANIX or AYTU more profitable?

Does the media prefer ANIX or AYTU?

Do institutionals and insiders have more ownership in ANIX or AYTU?

Do analysts rate ANIX or AYTU?

Summary

How does Aytu BioPharma compare to ALT5 Sigma?

Which has preferable valuation & earnings, AYTU or AIFC?

Do institutionals & insiders have more ownership in AYTU or AIFC?

Is AYTU or AIFC more profitable?

Does the media prefer AYTU or AIFC?

Do analysts prefer AYTU or AIFC?

Which has more volatility and risk, AYTU or AIFC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AYTU vs. The Competition

Aytu BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools